公开(公告)号：US11795222B2

公开(公告)日：2023-10-24

申请号：US16979323

申请日：2019-03-12

Applicant: INNATE PHARMA

Inventor： Agnes Boyer-Chammard ,  Pierre Dodion ,  Roger Cohen

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2863 ,  C07K16/30 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.